{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T12:46:30Z","timestamp":1775911590966,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Cannabinoids are widely recognized for their potential therapeutic effects, making them significant and valuable candidates for medical research and applications across various fields. This review aims to analyze the pharmacokinetics of Cannabidiol (CBD), Cannabigerol (CBG), and Cannabichromene (CBC), along with their corresponding acidic forms, Cannabidiolic acid (CBDA), Cannabigerolic acid (CBGA), and Cannabichromenic acid (CBCA). Among these cannabinoids, CBD is the most extensively studied. Nevertheless, research involving all the mentioned cannabinoids has shown that their pharmacokinetic parameters are highly variable, depending significantly on factors such as dose, formulation, route of administration, and diet. Furthermore, challenges such as brain penetration and first-pass metabolism have been highlighted. In conclusion, this review demonstrates significant progress in understanding the pharmacokinetics of non-psychotropic cannabinoids. However, it also underscores the need for further research, particularly on CBG, CBC, and their respective acidic forms, with the most significant gap being in clinical investigations. Expanding these studies is essential to facilitate their optimized use in medical treatments.<\/jats:p>","DOI":"10.3390\/pharmaceutics17020236","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T04:37:04Z","timestamp":1739335024000},"page":"236","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetics of Non-Psychotropic Phytocannabinoids"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9228-6322","authenticated-orcid":false,"given":"Mariana","family":"Lacerda","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-210X","authenticated-orcid":false,"given":"Andreia","family":"Carona","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"},{"name":"CIBIT, Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3004-531 Coimbra, Portugal"}]},{"given":"Sara","family":"Castanheira","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3854-6549","authenticated-orcid":false,"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"},{"name":"CIBIT, Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3004-531 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-1671","authenticated-orcid":false,"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"},{"name":"CIBIT, Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3004-531 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6981-6639","authenticated-orcid":false,"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology and Pharmaceutical Sciences, Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal"},{"name":"CIBIT, Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, 3004-531 Coimbra, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Radwan, M.M., Chandra, S., Gul, S., and Elsohly, M.A. (2021). Cannabinoids, Phenolics, Terpenes and Alkaloids of Cannabis. Molecules, 26.","DOI":"10.3390\/molecules26092774"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: Origins and Biosynthesis","volume":"25","year":"2020","journal-title":"Trends Plant Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Walsh, K.B., McKinney, A.E., and Holmes, A.E. (2021). Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.777804"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Drug Delivery Reviews Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal Chemical Properties of Successful Central Nervous System Drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRX"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ptr.7742","article-title":"Nanoformulations as a Strategy to Overcome the Delivery Limitations of Cannabinoids","volume":"37","author":"Reddy","year":"2023","journal-title":"Phytother. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","article-title":"Plasma and Brain Pharmacokinetic Profile of Cannabidiol (CBD), Cannabidivarine (CBDV), \u03949-Tetrahydrocannabivarin (THCV) and Cannabigerol (CBG) in Rats and Mice Following Oral and Intraperitoneal Administration and CBD Action on Obsessive-Compulsive Behaviour","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s13311-015-0374-6","article-title":"The Endocannabinoid System and Its Modulation by Phytocannabinoids","volume":"12","author":"Piscitelli","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Di Salvo, A., Conti, M.B., and della Rocca, G. (2023). Pharmacokinetics, Efficacy, and Safety of Cannabidiol in Dogs: An Update of Current Knowledge. Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1204526"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Matei, D., Trofin, D., Iordan, D.A., Onu, I., Condurache, I., Ionite, C., and Buculei, I. (2023). The Endocannabinoid System and Physical Exercise. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24031989"},{"key":"ref_11","unstructured":"(2024, June 19). Food and Drug Administration FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol, Available online: https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd."},{"key":"ref_12","unstructured":"(2024, June 19). Infarmed Relat\u00f3rio P\u00fablico De Avalia\u00e7\u00e3o Do Pedido De Comparticipa\u00e7\u00e3o De Medicamento Para Uso Humano. Available online: https:\/\/www.infarmed.pt\/documents\/15786\/1437513\/Relat%FF%FFrio%2Bp%FF%FFblico%2Bde%2Bavalia%FF%FF%FF%FFo%2Bdo%2Bmedicamento%2BSativex%2B2019\/c055642c-92fe-4e84-9da6-f72f3a9c0e06."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/biof.2078","article-title":"Anticancer Effect of Minor Phytocannabinoids in Preclinical Models of Multiple Myeloma","volume":"50","author":"Aguzzi","year":"2024","journal-title":"BioFactors"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101998","DOI":"10.1016\/j.arr.2023.101998","article-title":"Under the Umbrella of Depression and Alzheimer\u2019s Disease Physiopathology: Can Cannabinoids Be a Dual-Pleiotropic Therapy?","volume":"90","author":"Fonseca","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like Effect of \u03949-Tetrahydrocannabinol and Other Cannabinoids Isolated from Cannabis sativa L.","volume":"95","author":"Ivey","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"113458","DOI":"10.1016\/j.fct.2022.113458","article-title":"Evaluation of the Anti-Inflammatory Effects of Selected Cannabinoids and Terpenes from Cannabis Sativa Employing Human Primary Leukocytes","volume":"170","author":"Blevins","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Galletta, M., Reekie, T.A., Nagalingam, G., Bottomley, A.L., Harry, E.J., Kassiou, M., and Triccas, J.A. (2020). Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080523"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Huntsman, R.J., Tang-Wai, R., Alcorn, J., Vuong, S., Acton, B., Corley, S., Laprairie, R., Lyon, A.W., Meier, S., and Mousseau, D.D. (2019). Dosage Related Efficacy and Tolerability of Cannabidiol in Children with Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study. Front. Neurol., 10.","DOI":"10.3389\/fneur.2019.00716"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1042\/CS20220193","article-title":"Antiviral Activities of Hemp Cannabinoids","volume":"137","author":"Simchuk","year":"2023","journal-title":"Clin. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.apsb.2021.01.014","article-title":"Intranasal Temperature-Sensitive Hydrogels of Cannabidiol Inclusion Complex for the Treatment of Post-Traumatic Stress Disorder","volume":"11","author":"Pang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1111\/cts.13685","article-title":"Pharmacokinetics and Pharmacodynamics of Cannabis-based Medicine in a Patient Population Included in a Randomized, Placebo-controlled, Clinical Trial","volume":"17","author":"Hansen","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acs.jnatprod.9b00600","article-title":"Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome","volume":"82","author":"Anderson","year":"2019","journal-title":"J. Nat. Prod."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1111\/bph.15661","article-title":"Cannabigerolic Acid, a Major Biosynthetic Precursor Molecule in Cannabis, Exhibits Divergent Effects on Seizures in Mouse Models of Epilepsy","volume":"178","author":"Anderson","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40263-020-00741-5","article-title":"Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications","volume":"34","author":"Perucca","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Millar, S.A., Stone, N.L., Yates, A.S., and O\u2019Sullivan, S.E. (2018). A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01365"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Millar, S.A., Maguire, R.F., Yates, A.S., and O\u2019Sullivan, S.E. (2020). Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals, 13.","DOI":"10.3390\/ph13090219"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hossain, K.R., Alghalayini, A., and Valenzuela, S.M. (2023). Current Challenges and Opportunities for Improved Cannabidiol Solubility. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914514"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1124\/dmd.120.000350","article-title":"Cytochrome P450\u2013Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol","volume":"49","author":"Beers","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Batinic, A., Sutlovi\u0107, D., Kuret, S., Matana, A., Kumric, M., Bozic, J., and Dujic, Z. (2023). Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study. Pharmaceuticals, 16.","DOI":"10.3390\/ph16050645"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, C., Cai, A., Li, H., Deng, N., Cho, B.P., Seeram, N.P., and Ma, H. (2022). Characterization of Molecular Interactions between Cannabidiol and Human Plasma Proteins (Serum Albumin and \u03b3-Globulin) by Surface Plasmon Resonance, Microcalorimetry, and Molecular Docking. J. Pharm. Biomed. Anal., 214.","DOI":"10.1016\/j.jpba.2022.114750"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122872","DOI":"10.1016\/j.ijpharm.2023.122872","article-title":"Cannabidiol\u2013Loaded Biomimetic Macrophage Membrane Vesicles against Post\u2013Traumatic Stress Disorder Assisted by Ultrasound","volume":"637","author":"Li","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1124\/dmd.120.000270","article-title":"Maternal and Fetal Pharmacokinetic Analysis of Cannabidiol during Pregnancy in Mice","volume":"49","author":"Ochiai","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Chicoine, A., Illing, K., Vuong, S., Pinto, K.R., Alcorn, J., and Cosford, K. (2020). Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. Front. Vet. Sci., 7.","DOI":"10.3389\/fvets.2020.583404"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Limsuwan, S., Phonsatta, N., Panya, A., Asasutjarit, R., and Tansakul, N. (2024). Pharmacokinetics Behavior of Four Cannabidiol Preparations Following Single Oral Administration in Dogs. Front. Vet. Sci., 11.","DOI":"10.3389\/fvets.2024.1389810"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wakshlag, J.J., Schwark, W.S., Deabold, K.A., Talsma, B.N., Cital, S., Lyubimov, A., Iqbal, A., and Zakharov, A. (2020). Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, \u03949-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing with Three Oral Forms of Hemp Extract. Front. Vet. Sci., 7.","DOI":"10.3389\/fvets.2020.00505"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Polidoro, D., Temmerman, R., Devreese, M., Charalambous, M., Van Ham, L., Cornelis, I., Broeckx, B.J.G., Mandigers, P.J.J., Fischer, A., and Storch, J. (2022). Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs. Front. Vet. Sci., 9.","DOI":"10.3389\/fvets.2022.899940"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"della Rocca, G., Paoletti, F., Conti, M.B., Galarini, R., Chiaradia, E., Sforna, M., Dall\u2019Aglio, C., Polisca, A., and Di Salvo, A. (2023). Pharmacokinetics of Cannabidiol Following Single Oral and Oral Transmucosal Administration in Dogs. Front. Vet. Sci., 9.","DOI":"10.3389\/fvets.2022.1104152"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.2174\/1389200217666160406120509","article-title":"Drug-Metabolizing Enzymes and Efflux Transporters in Nasal Epithelium: Influence on the Bioavailability of Intranasally Administered Drugs","volume":"17","author":"Oliveira","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neubiorev.2005.04.005","article-title":"Maternal Smoking, Drinking or Cannabis Use during Pregnancy and Neurobehavioral and Cognitive Functioning in Human Offspring","volume":"30","author":"Huizink","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12978-020-0880-9","article-title":"Cannabis Use during Pregnancy and Its Relationship with Fetal Developmental Outcomes and Psychiatric Disorders. A Systematic Review","volume":"17","author":"Roncero","year":"2020","journal-title":"Reprod. Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/CHI.0b013e3181bfa8ee","article-title":"Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R Study","volume":"48","author":"Tiemeier","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejpb.2020.06.021","article-title":"Pharmacokinetic Investigation of Synthetic Cannabidiol Oral Formulations in Healthy Volunteers","volume":"154","author":"Izgelov","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Abbotts, K.S.S., Ewell, T.R., Butterklee, H.M., Bomar, M.C., Akagi, N., Dooley, G.P., and Bell, C. (2022). Cannabidiol and Cannabidiol Metabolites: Pharmacokinetics, Interaction with Food, and Influence on Liver Function. Nutrients, 14.","DOI":"10.3390\/nu14102152"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/ptr.6651","article-title":"Evaluation of Pharmacokinetics and Acute Anti-inflammatory Potential of Two Oral Cannabidiol Preparations in Healthy Adults","volume":"34","author":"Hobbs","year":"2020","journal-title":"Phytother. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jat\/bkab026","article-title":"Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants","volume":"46","author":"Peters","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/epi.16419","article-title":"A Phase 1, Randomized, Pharmacokinetic Trial of the Effect of Different Meal Compositions, Whole Milk, and Alcohol on Cannabidiol Exposure and Safety in Healthy Subjects","volume":"61","author":"Crockett","year":"2020","journal-title":"Epilepsia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jat\/bkab124","article-title":"Pharmacokinetic Profile of \u22069-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood Following Vaporization and Oral Ingestion of Cannabidiol Products","volume":"46","author":"Bergeria","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s40262-019-00841-6","article-title":"A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment","volume":"59","author":"Tayo","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1016\/j.xphs.2021.08.012","article-title":"Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study","volume":"110","author":"Devinsky","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/bcp.14617","article-title":"A Phase I Trial of the Safety, Tolerability and Pharmacokinetics of Cannabidiol Administered as Single-dose Oil Solution and Single and Multiple Doses of a Sublingual Wafer in Healthy Volunteers","volume":"87","author":"Hosseini","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Christensen, C., Rose, M., Cornett, C., and Alles\u00f8, M. (2023). Decoding the Postulated Entourage Effect of Medicinal Cannabis: What It Is and What It Isn\u2019t. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082323"},{"key":"ref_54","first-page":"3448","article-title":"Dietary Fats and Pharmaceutical Lipid Excipients Increase Systemic Exposure to Orally Administered Cannabis and Cannabis-Based Medicines","volume":"8","author":"Zgair","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Martinez Naya, N., Kelly, J., Corna, G., Golino, M., Polizio, A.H., Abbate, A., Toldo, S., and Mezzaroma, E. (2024). An Overview of Cannabidiol as a Multifunctional Drug: Pharmacokinetics and Cellular Effects. Molecules, 29.","DOI":"10.3390\/molecules29020473"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1089\/can.2023.0066","article-title":"Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain","volume":"8","author":"Moore","year":"2023","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00228-021-03232-8","article-title":"Pharmacokinetics of Cannabichromene in a Medical Cannabis Product Also Containing Cannabidiol and \u03949-Tetrahydrocannabinol: A Pilot Study","volume":"78","author":"Peters","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/acs.jnatprod.3c00336","article-title":"Elucidating the Mechanism of Metabolism of Cannabichromene by Human Cytochrome P450s","volume":"87","author":"Roy","year":"2024","journal-title":"J. Nat. Prod."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116654","DOI":"10.1016\/j.taap.2023.116654","article-title":"Hepatic Biotransformation of Non-Psychotropic Phytocannabinoids and Activity Screening on Cytochromes P450 and UDP-Glucuronosyltransferases","volume":"476","author":"Havlasek","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pavlovic, R., Nenna, G., Calvi, L., Panseri, S., Borgonovo, G., Giupponi, L., Cannazza, G., and Giorgi, A. (2018). Quality Traits of \u201cCannabidiol Oils\u201d: Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations. Molecules, 23.","DOI":"10.3390\/molecules23051230"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1373\/clinchem.2016.263475","article-title":"Free and Glucuronide Whole Blood Cannabinoids\u2019 Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake","volume":"62","author":"Newmeyer","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/dta.2092","article-title":"Cannabinoid Disposition in Oral Fluid after Controlled Smoked, Vaporized, and Oral Cannabis Administration","volume":"9","author":"Swortwood","year":"2017","journal-title":"Drug Test. Anal."},{"key":"ref_63","first-page":"408","article-title":"Detection of Cannabigerol and Its Presumptive Metabolite in Human Urine After Cannabis Consumption","volume":"65","author":"Somogyi","year":"2010","journal-title":"Pharmazie"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1373\/clinchem.2016.265371","article-title":"Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting \u03949-Tetrahydrocannabinol in Blood and Oral Fluid Following Cannabis Brownie Administration","volume":"63","author":"Newmeyer","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1089\/can.2023.0174","article-title":"Impact of Dietary Fat and Oral Delivery System on Cannabigerol Pharmacokinetics in Adults","volume":"9","author":"Story","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Johns, T.N., Wakshlag, J.J., Lyubimov, A.V., Zakharov, A., and Burnside, W.M. (2023). Pharmacokinetics of Cannabidiol-\/Cannabidiolic Acid-Rich Hemp Oil in Juvenile Cynomolgus Macaques (Macaca fascicularis). Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1286158"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Busard\u00f2, F.P., P\u00e9rez-Acevedo, A.P., Pacifici, R., Mannocchi, G., Gottardi, M., Papaseit, E., P\u00e9rez-Ma\u00f1\u00e1, C., Martin, S., Poyatos, L., and Pichini, S. (2021). Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010059"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","article-title":"Pharmacological Effects of Formulation Vehicles","volume":"42","author":"Verweij","year":"2003","journal-title":"Clin. Pharmacokinet."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/2\/236\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:31:54Z","timestamp":1760027514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/2\/236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["pharmaceutics17020236"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17020236","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}